Literature DB >> 12866710

Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines.

Lucyna Antkiewicz-Michaluk1.   

Abstract

The cause of chronic nigral cell death in Parkinson's disease (PD) and the underlying mechanisms remain elusive. The selective action of exogenous and endogenous neurotoxic substances can provide partial explanation of these processes. 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) is an exogenous neurotoxin producing parkinsonism in humans, monkeys and various animals as the result of MAOB-catalyzed conversion of it to the 1-methyl-4-phenyl-pyridinium ion (MPP+), which selectively kills the nigrostriatal dopaminergic neurons. On the other hand, various isoquinoline derivatives were found in the brain, and they are considered to be the endogenous neurotoxins with neurochemical properties similar to those of MPTP, which cause PD. Among them, 1,2,3,4-tetrahydroisoquinoline (TIQ), 1-benzyl-TIQ, and 1-methyl-5,6-dihydroxy-TIQ (salsolinol) have the most potent neurotoxic action. Since PD is a slowly progressing neurodegenerative disease, it has been suggested that it could be connected with excitotoxicity and apoptosis. Therapeutic strategies should focused on the search for the drugs exhibiting antiapoptotic potential such as: antioxidants, MAOB inhibitors, dopaminergic drugs and free radical scavengers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12866710

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  12 in total

1.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

Review 2.  Not Just from Ethanol. Tetrahydroisoquinolinic (TIQ) Derivatives: from Neurotoxicity to Neuroprotection.

Authors:  Alessandra T Peana; Valentina Bassareo; Elio Acquas
Journal:  Neurotox Res       Date:  2019-05-02       Impact factor: 3.911

3.  Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease.

Authors:  Bruk Getachew; Antonei B Csoka; Amna Bhatti; Robert L Copeland; Yousef Tizabi
Journal:  Neurotox Res       Date:  2020-06-22       Impact factor: 3.911

4.  Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.

Authors:  Kiyoshi Ando; Jun Maeda; Motoki Inaji; Takashi Okauchi; Shigeru Obayashi; Makoto Higuchi; Tetsuya Suhara; Yoshikuni Tanioka
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

5.  Different mechanisms of NMDA-mediated protection against neuronal apoptosis: a stimuli-dependent effect.

Authors:  Danuta Jantas; Wladyslaw Lason
Journal:  Neurochem Res       Date:  2009-05-22       Impact factor: 3.996

Review 6.  An inducible MAO-B mouse model of Parkinson's disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics.

Authors:  Manish Chamoli; Shankar J Chinta; Julie K Andersen
Journal:  J Neural Transm (Vienna)       Date:  2018-04-30       Impact factor: 3.575

Review 7.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

Review 8.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

9.  Salsolinol, an endogenous compound triggers a two-phase opposing action in the central nervous system.

Authors:  Edyta Możdżeń; Małgorzata Kajta; Agnieszka Wąsik; Tomasz Lenda; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2014-12-24       Impact factor: 3.911

10.  Dose-dependent effect of Curcuma longa for the treatment of Parkinson's disease.

Authors:  Xiao-Wei Ma; Rui-You Guo
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.